Exd391209

Exd391209 is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed by Chengdu Aoda Biotechnology for the treatment of obesity and overweight. As a GLP-1 analog, it mimics the physiological actions of the endogenous incretin hormone GLP-1, which is secreted by the intestines in response to food intake. The drug works by activating GLP-1 receptors, leading to enhanced glucose-dependent insulin secretion, suppression of glucagon release, and a delay in gastric emptying. In the context of weight management, Exd391209 acts on the central nervous system to promote satiety and reduce appetite, thereby facilitating weight loss. It is designed with a prolonged half-life to allow for infrequent (likely weekly) subcutaneous administration, aiming to improve patient compliance in chronic metabolic management.